VCYT · Veracyte, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on VCYT. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About VCYT · Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Live Quote
BUY (score +7) · 12-1 mom 68.1% · RSI 72.1 · above_both · 0.0% from high
Targets blend Wall Street consensus (10 analysts: low $37.00 / mean $49.10 / high $57.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.
Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.
Veracyte presents a well-functioning diagnostics company with strong fundamentals and multiple positive catalysts — landmark Phase III ASCO data (OPTIMA for Prosigna, ENZAMET for Decipher Prostate), commercial US launch of Prosigna, and Medicare coverage secured for TrueMRD. However, the investigation trigger referencing insider open-market P/S clustering does not hold up under scrutiny: all 30 recent Form 4 filings are routine — RSU vesting at $0 strike (code A), tax-withholding sells (code F), or pre-scheduled Rule 10b5-1 plan sales (code S). Zero true discretionary open-market purchases from any insider. The stock is also near 52-week high, RSI=74.4 (overbought), and forward P/E of ~26x with EV/EBITDA of ~34x represents full valuation in a high-quality but richly priced name.